FilingReader Intelligence
Nxera unveils obesity drug pipeline after Pfizer discontinuation
August 5, 2025 at 11:39 PM UTC•By FilingReader AI
Nxera Pharma launched a pipeline of obesity therapies, including a proprietary oral GLP-1 agonist and six additional programs targeting GIP, Amylin, and Apelin receptors.
The expansion follows Pfizer's discontinuation of PF-06954522, a separate GLP-1 agonist discovered with Nxera, due to a portfolio decision. The obesity market is projected to exceed $100bn annually.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
TSE:4565•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Sosei Group Corporation publishes news
Free account required • Unsubscribe anytime